Trade Inovio Pharmaceuticals, Inc. - INO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0522 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023624% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001401% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.5389 |
| Open | 1.4639 |
| 1-Year Change | -87.57% |
| Day's Range | 1.4239 - 1.5789 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 4, 2025 | 1.5289 | -0.0100 | -0.65% | 1.5389 | 1.5489 | 1.4789 |
| Apr 3, 2025 | 1.5689 | -0.0250 | -1.57% | 1.5939 | 1.5939 | 1.5089 |
| Apr 2, 2025 | 1.6189 | 0.1400 | 9.47% | 1.4789 | 1.6489 | 1.4489 |
| Apr 1, 2025 | 1.4789 | -0.1300 | -8.08% | 1.6089 | 1.6089 | 1.4789 |
| Mar 31, 2025 | 1.5989 | -0.0600 | -3.62% | 1.6589 | 1.6589 | 1.5789 |
| Mar 28, 2025 | 1.6989 | -0.0400 | -2.30% | 1.7389 | 1.7389 | 1.6589 |
| Mar 27, 2025 | 1.7289 | 0.0150 | 0.88% | 1.7139 | 1.7489 | 1.6789 |
| Mar 26, 2025 | 1.7189 | -0.0750 | -4.18% | 1.7939 | 1.7939 | 1.6989 |
| Mar 25, 2025 | 1.7789 | -0.0900 | -4.82% | 1.8689 | 1.8689 | 1.7489 |
| Mar 24, 2025 | 1.8489 | -0.0700 | -3.65% | 1.9189 | 1.9289 | 1.8489 |
| Mar 21, 2025 | 1.8989 | -0.0150 | -0.78% | 1.9139 | 1.9489 | 1.8439 |
| Mar 20, 2025 | 1.9189 | -0.0100 | -0.52% | 1.9289 | 1.9839 | 1.8989 |
| Mar 19, 2025 | 1.9289 | -0.1350 | -6.54% | 2.0639 | 2.0939 | 1.8989 |
| Mar 18, 2025 | 2.0539 | -0.0400 | -1.91% | 2.0939 | 2.0989 | 1.9589 |
| Mar 17, 2025 | 2.0889 | 0.0100 | 0.48% | 2.0789 | 2.1389 | 2.0089 |
| Mar 14, 2025 | 1.9989 | 0.0550 | 2.83% | 1.9439 | 2.0089 | 1.9289 |
| Mar 13, 2025 | 1.9089 | -0.0750 | -3.78% | 1.9839 | 2.0439 | 1.8889 |
| Mar 12, 2025 | 2.0189 | 0.0750 | 3.86% | 1.9439 | 2.0489 | 1.9289 |
| Mar 11, 2025 | 1.9189 | 0.0050 | 0.26% | 1.9139 | 1.9589 | 1.8839 |
| Mar 10, 2025 | 1.9189 | 0.0350 | 1.86% | 1.8839 | 1.9489 | 1.8739 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Inovio Pharmaceuticals Company profile
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system''s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.| Industry: | Biotechnology & Medical Research (NEC) |
6769 Mesa Ridge Rd.
SAN DIEGO
CALIFORNIA 92121
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com